Metropolis Healthcare Limited — Important, 06-01-2025: Updates

Metropolis Healthcare reported strong operational performance for Q3FY25, achieving approximately 11% revenue growth year-on-year, despite the seasonally lean period for diagnostics, particularly in the West and South regions. The growth was driven by increased patient and test volumes, as well as favorable changes in product mix and realization benefits. The B2C segment saw impressive mid-teens growth, while the B2B segment grew in low double-digits. Notably, the Truhealth wellness and bundling segment emerged as the fastest-growing category, with around 25% growth for the quarter. The company remains optimistic about future growth and margin expansion, considering potential price adjustments in the B2C segment and exploring inorganic growth opportunities. With cash reserves of approximately INR 200 crores and a debt-free status, the firm is well-positioned to seize growth opportunities. Shareholders can look forward to a positive outlook for the upcoming period.